Literature DB >> 15003637

Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.

Anke Huckriede1, Laura Bungener, Marijke Holtrop, Jacqueline de Vries, Barry-Lee Waarts, Toos Daemen, Jan Wilschut.   

Abstract

For the rational design of vaccines capable of inducing CD8+ T cell responses knowledge of the identity of the antigen-presenting cell (APC) and the mechanism of antigen presentation is very important. Here, we address these issues for alphavirus-based immunization, in particular immunization with recombinant Semliki Forest virus (rSFV). Studies with dendritic cells (DCs) from various origins revealed that rSFV has a very limited capacity to transfect this cell type in vitro. To further investigate in vivo whether rSFV transfects professional antigen-presenting cells directly or whether the antigens reach APCs via a mechanism of cross-priming we compared the immunological effects of three different SFV-constructs encoding the influenza nucleoprotein (NP). These constructs differ in the amount of NP produced per cell or in the stability of the NP, respectively. Induction of cytotoxic T lymphocytes (CTLs) appeared to benefit from a large amount of stable antigen. In contrast, rapid antigen degradation, and thus availability of antigenic peptides in the transfected cell, was found to be disadvantageous. Based on these in vitro and in vivo results, we hypothesize that antigen presentation after SFV-based immunization proceeds via a mechanism in which APCs are not transfected directly but acquire antigen from other transfected cells and present it to CTLs in a process of cross-priming.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003637     DOI: 10.1016/j.vaccine.2003.10.003

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

Authors:  M E Fluet; A C Whitmore; D A Moshkoff; K Fu; Y Tang; M L Collier; A West; D T Moore; R Swanstrom; R E Johnston; N L Davis
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

2.  An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice.

Authors:  Angel A Oñate; Gabriel Donoso; Gustavo Moraga-Cid; Hugo Folch; Sandra Céspedes; Edilia Andrews
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88.

Authors:  Asa S Hidmark; Gerald M McInerney; Eva K L Nordström; Iyadh Douagi; Kristen M Werner; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Influenza A virus-specific CD8 T-cell responses: from induction to function.

Authors:  Mr Olson; Be Russ; Pc Doherty; Sj Turner; J Stambas
Journal:  Future Virol       Date:  2010-03-01       Impact factor: 1.831

Review 5.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

6.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

7.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.

Authors:  Georg Gasteiger; Wolfgang Kastenmuller; Ronny Ljapoci; Gerd Sutter; Ingo Drexler
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

9.  The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.

Authors:  Joseph M Thompson; Alan C Whitmore; Herman F Staats; Robert Johnston
Journal:  Vaccine       Date:  2008-07-24       Impact factor: 3.641

10.  Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Authors:  Andreas Mörner; Iyadh Douagi; Mattias N E Forsell; Christopher Sundling; Pia Dosenovic; Sijy O'Dell; Barna Dey; Peter D Kwong; Gerald Voss; Rigmor Thorstensson; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.